UROTHELIAL CARCINOMA BLADDER
Clinical trials for UROTHELIAL CARCINOMA BLADDER explained in plain language.
Never miss a new study
Get alerted when new UROTHELIAL CARCINOMA BLADDER trials appear
Sign up with your email to follow new studies for UROTHELIAL CARCINOMA BLADDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo shows promise in advanced cancers
Disease control CompletedThis phase 2 trial tested a new cancer vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The study enrolled 63 participants to see if the combination is safe a…
Matched conditions: UROTHELIAL CARCINOMA BLADDER
Phase: PHASE2 • Sponsor: IO Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental combo aims to supercharge cancer immunotherapy
Disease control CompletedThis early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …
Matched conditions: UROTHELIAL CARCINOMA BLADDER
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New bladder cancer drug shows early promise in small trial
Disease control CompletedThis early-phase trial tested a new drug called UGN-301 (zalifrelimab) given directly into the bladder for people with recurrent non-muscle invasive bladder cancer. The study included 51 participants and aimed to check safety and find the right dose, both alone and with other dru…
Matched conditions: UROTHELIAL CARCINOMA BLADDER
Phase: PHASE1 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC